Interleukin-6: a new therapeutic target in systemic sclerosis?

Clinical and Translational Immunology

Volumn 2, Issue 4, 2013, Pages

  O'Reilly, Steven ^a   Cant, Rachel ^a   Ciechomska, Marzena ^a   van Laar, Jacob M ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

fibrosis; interleukin 6; interleukin 6 signalling; systemic sclerosis; Th17

Indexed keywords

EID: 84898071275     PISSN: None     EISSN: 20500068     Source Type: Journal    
DOI: 10.1038/cti.2013.2     Document Type: Review

References (59)

1. Ohtsuka T. Serum interleukin-6 level is reflected in elevated high-sensitivity C-reactive protein level in patients with systemic sclerosis. J Dermatol 2010; 37: 801–806.
2. Fleischmajer R, Perlish JS, Reeves JR. Cellular infiltrates in scleroderma skin. Arthr Rheum 1977; 20: 975–984.
3. Roumm AD, Whiteside TL, Medsger TA, Rodnan GP. Lymphocytes in the skin of patients with progressive systemic sclerosis. Arthr Rheumat 1984; 27: 645–653.
4. Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 2002; 13: 357–368.
5. Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000; 95: 56–61.
6. Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G et al. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 1998; 187: 461–468.
7. Samoilova EB, Horton JL, Hilliard B, Liu T-ST, Chen Y. IL-6-Deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. J Immunol 1998; 161: 6480–6486.
8. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001; 27: 140–146.
9. Muraguchi A, Kishimoto T, Miki Y, Kuritani T, Kaieda T, Yoshizaki K et al. T cell-replacing factor- (TRF) induced IgG secretion in a human B blastoid cell line and demonstration of acceptors for TRF. J Immunol 1981; 127: 412–416.
10. Teranishi T, Hirano T, Arima N, Onoue K. Human helper T cell factor(s) (ThF). II. Induction of IgG production in B lymphoblastoid cell lines and identification of T cell-replacing factor- (TRF) like factor(s). J Immunol 1982; 128: 1903–1908.
11. Jenkins BJ, Roberts AW, Najdovska M, Grail D, Ernst M. The threshold of gp130-dependent STAT3 signaling is critical for normal regulation of hematopoiesis. Blood 2005; 105: 3512–3520.
12. Gearing DP, Comeau MR, Friend DJ, Gimpel SD, Thut CJ, McGourty J et al. The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. Science 1992; 255: 1434–1437.
13. Stahl N, Boulton T, Farruggella T, Ip N, Davis S, Witthuhn B et al. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science 1994; 263: 92–95.
14. Matthews V, Schuster B, Schütze S, Bussmeyer I, Ludwig A, Hundhausen C et al. Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem 2003; 278: 38829–38839.
15. Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011; 121: 3375–3383.
16. Vermes C, Jacobs JJ, Zhang J, Firneisz G, Roebuck KA, Glant TT. Shedding of the interleukin-6 (IL-6) receptor (gp80) determines the ability of IL-6 to induce gp130 phosphorylation in human osteoblasts. J Biol Chem 2002; 277: 16879–16887.
17. Mülberg J, Schooltink H, Stoyan T, Günther M, Graeve L, Buse G et al. The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol 1993; 23: 473–480.
18. Horiuchi S, Koyanagiu Y, Zhouu Y, Miyamotou H, Tanakau Y, Waki M et al. Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur J Immunol 1994; 24: 1945–1948.
19. Althoff K, Reddy P, Voltz N, Rose-John S, Müllberg J. Shedding of interleukin-6 receptor and tumor necrosis factor α. Eur J Biochem 2000; 267: 2624–2631.
20. Müllberg J, Durie FH, Otten-Evans C, Alderson MR, Rose-John S, Cosman D et al. A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J Immunol 1995; 155: 5198–5205.
21. Jones SA, Novick D, Horiuchi S, Yamamoto N, Szalai AJ, Fuller GM. C-reactive protein: a physiological activator of interleukin 6 receptor shedding. J Exp Med 1999; 189: 599–604.
22. Khan K, Xu S, Nihtyanova S, Derrett-Smith E, Abraham D, Denton CP et al. Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann Rheum Dis 2012; 71: 1235–1242.
23. Vollmer P, Walev I, Rose-John S, Bhakdi S. Novel pathogenic mechanism of microbial metalloproteinases: liberation of membrane-anchored molecules in biologically active form exemplified by studies with the human interleukin-6 receptor. Infect Immun 1996; 64: 3646–3651.
24. Terao M, Murota H, Kitaba S, Katayama I. Tumor necrosis factor-α processing inhibitor-1 inhibits skin fibrosis in a bleomycin-induced murine model of scleroderma. Exp Dermatol 2010; 19: 38–43.
25. Chalaris A, Rabe B, Paliga K, Lange H, Laskay T, Fielding CA et al. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood 2007; 110: 1748–1755.
26. Kahaleh B. The microvascular endothelium in scleroderma. Rheumatology 2008; 47: v14–v15.
27. Muangchan C, Pope JE. Interleukin 6 in systemic sclerosis and potential implications for targeted therapy. J Rheumatol 2012; 39: 1120–1124.
28. Cénit MC, Simeón CP, Vonk MC, Callejas-Rubio JL, Espinosa G, Carreira P et al. Influence of the IL6 gene in susceptibility to systemic sclerosis. J Rheumatol 2012; 39: 2294–2302.
29. Needleman BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor α, and interferon-γ levels in sera from patients with scleroderma. Arthr Rheumat 1992; 35: 67–72.
30. Hasegawa M, Sato S, Ihn H, Takehara K. Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Rheumatology 1999; 38: 612–617.
31. Hügle T, O'Reilly S, Simpson R, Kraaij MD, Bigley V, Collin M et al. Tumor necrosis factor co-stimulated T-lymphocytes from patients with systemic sclerosis trigger collagen production in fibroblasts. Arthr Rheumat 2012; 65: 481–491 n/a-n/a.
32. Hügle T, O'Reilly S, Simpson R, Kraaij MD, Bigley V, Collin M et al. Tumor necrosis factor–costimulated T lymphocytes from patients with systemic sclerosis trigger collagen production in fibroblasts. Arthr Rheumat 2013; 65: 481–491.
33. Kitaba S, Murota H, Terao M, Azukizawa H, Terabe F, Shima Y et al. Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol 2012; 180: 165–176.
34. O'Reilly S, Hügle T, van Laar JM. T cells in systemic sclerosis: a reappraisal. Rheumatology 2012; 51: 1540–1549.
35. Saito F, Tasaka S, Inoue K-i, Miyamoto K, Nakano Y, Ogawa Y et al. Role of interleukin-6 in bleomycin-induced lung inflammatory changes in mice. Am J Respir Cell Mol Biol 2008; 38: 566–571.
36. Kitaba S, Murota H, Terao M, Azukizawa H, Terabe F, Shima Y et al. Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol 2012; 180: 165–176.
37. Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 1993; 82: 1120–1126.
38. Harris TJ, Grosso JF, Yen H-R, Xin H, Kortylewski M, Albesiano E et al. Cutting edge: an in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol 2007; 179: 4313–4317.
39. Dees C, Tomcik M, Palumbo-Zerr K, Distler A, Beyer C, Lang V et al. JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis. Arthr Rheumat 2012; 64: 3006–3015.
40. O'Donoghue RJJ, Knight DA, Richards CD, Prêle CM, Lau HL, Jarnicki AG et al. Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis. EMBO Mol Med 2012; 4: 939–951.
41. O'Reilly S, Ciechomska M, Cant R, Hügle T, van Laar JM. Interleukin-6, its role in fibrosing conditions. Cytokine Growth Factor Rev 2012; 23: 99–107.
42. Kawaguchi Y, Hara M, Wright TM. Endogenous IL-1α from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 1999; 103: 1253–1260.
43. Andersen MB, Pingel J, Kjær M, Langberg H. Interleukin-6: a growth factor stimulating collagen synthesis in human tendon. J Appl Physiol 2011; 110: 1549–1554.
44. McFarland-Mancini MM, Funk HM, Paluch AM, Zhou M, Giridhar PV, Mercer CA et al. Differences in wound healing in mice with deficiency of IL-6 versus IL-6 receptor. J Immunol 2010; 184: 7219–7228.
45. Manoury B, Caulet-Maugendre S, Guénon I, Lagente V, Boichot E. TIMP-1 is a key factor of fibrogenic response to bleomycin in mouse lung. Int J Immunopathol Pharmacol 2006; 19: 471–487.
46. Silacci P, Dayer J-M, Desgeorges A, Peter R, Manueddu C, Guerne P-A. Interleukin (IL)-6 and its soluble receptor induce TIMP-1 expression in synoviocytes and chondrocytes, and block IL-1-induced collagenolytic activity. J Biol Chem 1998; 273: 13625–13629.
47. Smart DE, Vincent KJ, Arthur MJP, Eickelberg O, Castellazzi M, Mann J et al. JunD regulates transcription of the tissue inhibitor of metalloproteinases-1 and interleukin-6 genes in activated hepatic stellate cells. J Biol Chem 2001; 276: 24414–24421.
48. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann Rev Immunol 1989; 7: 145–173.
49. Sakkas LI, Chikanza IC, Platsoucas CD. Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheum 2006; 2: 679–685.
50. Yoshida H, Hashizume M, Mihara M. IL-6 blockade preferentially inhibits Th17 differentiation in collagen-induced arthritis. Rheumatol Int 2011; 31: 127–131.
51. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235–238.
52. Fenoglio D, Battaglia F, Parodi A, Stringara S, Negrini S, Panico N et al. Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis. Clin Immunol 2011; 139: 249–257.
53. Radstake TRDJ, van Bon L, Broen J, Wenink M, Santegoets K, Deng Y et al. Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFβ expression. PLoS ONE 2009; 4: e5981.
54. Mathian A, Parizot C, Dorgham K, Trad S, Arnaud L, Larsen M et al. Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions. Ann Rheum Dis 2013; 71: 1227–1234.
55. Meléndez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 2010; 56: 225–231.
56. Mir SA, Chatterjee A, Mitra A, Pathak K, Mahata SK, Sarkar S. Inhibition of signal transducer and activator of transcription 3 (STAT3) attenuates interleukin-6 (IL-6)-induced collagen synthesis and resultant hypertrophy in rat heart. J Biol Chem 2012; 287: 2666–2677.
57. Ma F, Li Y, Jia L, Han Y, Cheng J, Li H et al. Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF β/Smad activation and cardiac fibrosis induced by angiotensin II. PLoS ONE 2012; 7: e35144.
58. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371: 987–997.
59. Shima Y, Kuwahara Y, Murota H, Kitaba S, Kawai M, Hirano T et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology 2010; 49: 2408–2412.